N/A N=1,377 PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare
PrEP Precriptions for Reproductive Aged Women
Primary: PrEP Prescriptions — 11; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,120 FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women
HIV Infections
Primary: HIV Infection — 33; 35 participants
Phase 4 N=4,447 PrEP Implementation for Mothers in Antenatal Care
HIV Infections · Pregnancy Related
Primary: Maternal HIV Incidence — 0.38; 0.31 incidence/100 Person years
Phase 2 N=80 Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum
HIV Infections
Primary: Estimated Threshold of Maternal Steady-state Tenofovir Diphosphate (TFV-DP) Concentration Levels Corresponding to Optimal Adherence in the PK Component — 965; 1050…
N/A N=348 Monitoring Pre-exposure Prophylaxis for Young Adult Women
HIV/AIDS · Adherence
Primary: Enacted Adherence as Measured by Electronic Monitoring at 6 and 24 Months — 40.2; 36.8; 27.0; 26.6 percentage of adherence
Phase 4 N=212 Alignment of PrEP Use With HIV Risk in Young Women and Men
Pre-Exposure Prophylaxis · Sexually Transmitted Diseases, Bacterial · HIV Infections
Primary: Visits With PrEP Dispensation to Female Study Participants Reporting Sexual Behaviors or STI Symptoms — 211 Visits
N/A N=95 Packaging PrEP to Prevent HIV Among WWID
HIV/AIDS
Primary: PrEP Uptake at Week 1 — 63 Participants
Phase 4 N=427 Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study
HIV
Primary: Number of Participants With High Adherence at Six Months — 36; 40 Participants
Phase 3 N=54 The Women TAF-FTC Benchmark Study
HIV Infections
Primary: Frequency of Adverse Events — 69; 60; 62; 1 Number of adverse events
N/A N=960 PrEPARE: PrEP in Pregnancy, Accelerating Reach and Efficiency
Pre-Exposure Prophylaxis · HIV Infections · Pregnancy Related
Primary: PrEP Penetration — 30; 17; 46; 8 Participants
N/A N=67 WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)
HIV-infection/AIDS
Primary: Intervention Feasibility: Enrollment Rates Among Eligible Patients Screened — 67; 60; 27; 37 Participants
N/A N=106 Postpartum Pre-exposure Prophylaxis (PrEP) Study to Evaluate an Adherence Promotion Package for Postpartum Women on PrEP
HIV-1-infection
Primary: Recent PrEP Adherence — 33; 18 Participants — p=<0.001
N/A N=1,195 Evaluation of Pre-Exposure Prophylaxis (PrEP) in Pregnant and Breastfeeding Women
HIV-I Infection
Primary: Participants Initiating Pre-exposure Prophylaxis During Pregnancy — 1089 Participants
N/A N=150 PrEP My Way: A Novel PrEP Delivery System to Meet the Needs of Young African Women
HIV/AIDS
Primary: PrEP Adherence — 12; 4 Participants
N/A N=35 PrEP Communication Intervention for Female Clients of a Needle Exchange
HIV/AIDS
Primary: Change in PrEP Uptake and Adherence — 0; 1; 2; 3 Participants
Phase 1 N=13 Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW
HIV · Prophylaxis · Transgender
Primary: Change in Maximum Tenofovir Plasma (Cmax) Concentration — 286; 276; 274; 277 ng/mL
N/A N=189 The OPENS Trial: Offering Women PrEP (Aim 1)
Human Immunodeficiency Virus Transmission · Sexually Transmitted Diseases
Primary: PrEP Prescriptions (As Measured by Chart Review) — 1; 0 Participants — p=0.51
Phase 1 N=100 A Gender-Enhanced Pre-Exposure Prophylaxis (PrEP) Information-Motivational Workshop for Young South African Women
HIV Infections
Primary: Percent of Participants Who Have an Individual Counseling Session About PrEP. — 28; 28 Participants — p=1.0
Phase 3 N=304 Pre-Exposure Prophylaxis for Transgender Women in the US and South America
HIV Prevention
Primary: PrEP Uptake — 16.2; 11.4 days
N/A N=26 Pre-Exposure Prophylaxis in the Emergency Department
HIV/AIDS · PrEP
Primary: Engagement in Care (Implementation Component) — 1; 1 Participants
N/A N=46 Multi-component Intervention to Train Providers to Promote PrEP for Girls and Women in the Deep South
HIV Infections · Sexually Transmitted Diseases
Primary: Feasibility of Intervention Implementation — 4.28 Scores on a scale
Phase 4 N=140 Feasibility of Vaginal Progesterone to Reduce HIV-Associated Preterm Birth
PreTerm Birth
Primary: Adequate Adherence to Study Product — 62; 63 Participants
N/A N=132 Supporting Oral Pre-exposure Prophylaxis Decision Making Among Pregnant Women in Lilongwe, Malawi
HIV Prevention
Primary: Mean Acceptability of Intervention (AIM) Scale Score — 4.65; 4.52 score on a scale
N/A N=200 An Electronic Health Record-based Approach to Increase PrEP Knowledge and Uptake: the EMC2 PrEP Strategy
HIV Infections · Electronic Health Record · Primary Health Care
Primary: PrEP Uptake (Use) — 0; 0 Participants
N/A N=1,069 Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics
HIV Infections
Primary: Measurement of Acceptance Rate of PrEP — 921; 557 Participants
Phase 4 N=136 Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women
HIV Prevention
Primary: Adherence to PrEP — 22; 11; 30; 54 Participants
Early Phase 1 N=14 Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor
HIV/AIDS · Adherence, Medication · Drug Use
Primary: Baseline TFV (Tenofovir) Levels in Plasma
Phase 3 N=39 PK of TAF and TDF for PrEP in Pregnant and Postpartum Women
Hiv
Primary: Tenofovir Diphosphate (TFV-DP) Levels in Plasma and Intracellular Levels in Pregnant Women on Daily PrEP — 580; 71 TFV-DP PBMC (fmol/10^6cells)
Phase 1 N=10 Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract
HIV/AIDS
Primary: Average Tenofovir Diphosphate Concentrations in Mixed Rectal Cells During the Early (Low Estradiol) Follicular Phases of the Menstrual Cycle. — 406.14 fmol/million cells
Phase 2 N=594 Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
HIV Infection
Primary: Occurrence of Grade 3 or Higher Adverse Events (AEs) — 18; 24; 20; 28 Participants